Prenatal diagnosis of a 5q35.3 microduplication involving part of the ADAMTS2 locus: a likely benign variant without apparent phenotypic abnormality

Case series

Fagui Yue, MM,a,b, Yang Yu, MSc,a,b, Qi Xi, MSc,a,b, Hongguo Zhang, PhD,a,b, Yuting Jiang, MSc,a,b, Shibo Li, MD,c, Ruizhi Liu, MD, PhD,a,b, Ruixue Wang, PhD,a,b,*

Abstract

Rationale: Chromosomal duplications are associated with a series of genetic disorders. However, chromosome 5q duplications, especially pure 5q35.3 microduplications, have rarely been reported in the literature. Clinical phenotypes usually depend on the region of chromosome duplicated, its size, and loci.

Patient concerns: From 2011 to 2017, prenatal amniotic fluid samples were obtained from 6 pregnant women diagnosed with pure 5q35.3 microduplications following different prenatal indications at our center. We followed up the children of these pregnancies and determined their postnatal health conditions.

Diagnoses: Cytogenetic studies delineated that all patients had normal karyotypes, except for patient 6 who had 46,XX,inv(9) (p11q13). Single-nucleotide polymorphism array results showed 177–269 kb duplications of 5q35.3 (chr5:178728830–178997692) in these cases. All shared similar localization of ADAMTS2.

Interventions: All pregnant women chose to continue the pregnancies. Follow-up analysis showed that the children presented normal physical and growth developments.

Outcomes: We described six prenatal cases with similar 5q35.3 duplications involving part of the ADAMTS2 locus with no apparent postnatal phenotypic abnormalities.

Lessons: Our research revealed that partial microduplication of ADAMTS2 (chr5:178728830–178997692) might be benign and not correlate with disorders. And there might exist phenotypic diversities of 5q35.3 duplications.

Abbreviations: CMA = chromosomal microarray analysis, CNVs = copy number variations, DGV = database of genomic variants, FISH = Fluorescence in situ hybridization, ISCN 2013 = International System for Human Cytogenetic Nomenclature 2013, NCBI = National Center for Biotechnology Information, OMIM = Online Mendelian Inheritance in Man, SNP = single-nucleotide polymorphism.

Keywords: 5q35.3 microduplication, part of ADAMTS2, SNP array

1. Introduction

Chromosomal duplications are commonly associated with intellectual disability (ID) and related disorders. Three main common manifestations of 5q duplications have been seen in the clinic: distal 5q, interstitial, and terminal duplications, whereas Rodewald et al. divided 5q duplications into: the proximal duplication of 5q11-q22.1, the distal duplication of 5q31-qter, and the distal duplication of 5q34-qter. Other 5q duplication cases, such as 5q34 and 5q35, have also recently been described.

Pure partial 5q duplications are rare, and coverage regions range across the long arm. 5q duplications often occur in association with other chromosomal deletions, which makes it difficult to establish phenotype–karyotype correlations. Two explanations have been put forward to explain the common formations: an unbalanced segregation of a parental balanced translocation between 5q and another chromosome, and a homologous chromosome producing a partial monosomy of 5p and trisomy of 5q resulting from a parental inversion on
chromosome 5. The parental insertion or direct duplication can also result in a pure 5q duplication. Based on this information, it is not easy to determine the phenotypes of pure 5q duplications in the clinic.

For submicroscopic chromosomal imbalances and copy number variations (CNVs), the G-bandning technique is not suited to detecting structural aberrations; however, chromosomal microarray analysis (CMA) can improve the detection yield because of its superior diagnostic resolution. CMA is performed either as array comparative genomic hybridization or single-nucleotide polymorphism array. Subchromosomal abnormalities in approximately 1% of structurally normal pregnancies and 6% with structural abnormalities can be diagnosed by CMA of prenatal samples with normal karyotypes. It can also be used as a postnatal diagnostic tool for children with congenital abnormalities, developmental retardation, and intellectual disability.

Here, we delineated 6 cases of prenatal diagnostic 5q35.3 duplication presenting with a normal phenotypic spectrum using the single-nucleotide polymorphism (SNP) array. We also reviewed related clinical data focusing on similar duplicated segments, and discussed the potential pathogenicity of a 5q35.3 microduplication involving part of the ADAMTS2 locus.

2. Subjects and methods

2.1. Subjects

From 2011 to 2017, prenatal amniotic fluid samples were obtained from 6 pregnant women diagnosed with pure 5q35.3 microduplications following different prenatal indications at the Center for Reproductive Medicine and Center for Prenatal Diagnosis of the First Hospital of Jilin University. We followed up the children of these pregnancies and determined their postnatal health conditions. The study protocol was approved by the Ethics Committee of the First Hospital of Jilin University (No.2011–042), and all patients’ parents had provided informed consent for publication of the cases. All experiments in our study, including cytogentic analysis and molecular cytogenetics, were performed in accordance with relevant guidelines and standard protocols.

2.2. Cytogenetic analysis

Chromosome analysis was performed on G-band metaphases prepared from cultured amnion fluid cells according to standard protocols. Twenty metaphases were analyzed for all samples. The International System for Human Cytogenetic Nomenclature (ISCN 2013) was used to describe the karyotype.

2.3. SNP array

SNP array analysis was performed using the Human CytoSNP-12 BeadChip (Illumina, San Diego, CA). DNA was extracted from 10 mL of uncultured amnion fluid cells using the QIAamp DNA Mini kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. Image data were analyzed using Illumina’s Genome Studio software. The final results were analyzed using the Database of Chromosomal Imbalance and Phenotype in Humans using Ensemble Resources (DECIPHER), the database of genomic variants, Online Mendelian Inheritance in Man (OMIM), and the National Center for Biotechnology Information. Parents provided 5 mL of peripheral blood which was collected using a standard vacuum extraction blood-collecting system containing EDTA and heparin. Genomic DNA was then isolated from whole blood using the QIAamp DNA Mini kit (Qiagen) following the manufacturer’s instructions.

3. Results

From 2011 to 2017, a total of 6 cases with pure 5q35.3 duplications were initially detected by SNP array. All cases shared the similar duplication of part of the ADAMTS2 locus (chr5: 178728830–178772431). The distributions of indications for prenatal diagnosis were as follows: advanced maternal age (5/6), circular of umbilical cord (3/6), Down syndrome risk (2/6), abnormal hearing history (1/6), and early embryonic death in previous pregnancies (1/6). Routine cytogenetic analysis showed that all fetuses had normal karyotypes except for P6. Cytogenetic, SNP array, and clinical findings of all cases are summarized in Table 1. The parents of fetuses P2 and P3 chose to undergo SNP array analysis themselves based on the abnormal microarray results of their fetuses. Both fetuses were found to have inherited their 5q35.3 duplications from their paternal side. Neither of the 2 fathers presented with physical or developmental abnormalities. Among the 6 fetuses, the smallest duplication was 177kb, whereas the largest was 269kb.

P1 and P5 shared the same duplicated localizations, although they had different prenatal indications. We then carried out a follow-up of the fetuses in childhood including: pregnancy ultrasound results, body stature, developmental retardation, intellectual disability, craniofacial dysmorphisms, and skeletal anomalies. Our findings are listed in Table 1.

4. Discussion

We presented 6 rare prenatal cases with pure 5q35.3 duplications ranging from 177 to 269 kb according to SNP array. Two of these were identified as arising from paternal origins. To the best of our knowledge, the pathogenicity of duplicated CNV has not previously been described before. This is also the first report focusing on pure 5q35.3 duplications with no apparent phenotypic abnormalities. Moreover, most reported distal duplication of chromosome 5q is distributed between 5q35.2 and 5q35.3, and seldom involves single 5q35.3 duplications.

Chromosomal rearrangements such as duplications can result in a series of genetic diseases. Indeed, partial duplication of distal chromosome 5q is associated with a wide range of clinical phenotypes including short stature, growth and mental retardation, microcephaly, skeletal anomalies, facial clefts, micrognathia, low-set ears, hypertelorism, almond-shaped eyes, down-slanted palpebral fissures, strabismus, epicanthal folds, a prominent widened nasal bridge, a long philtrum, small mouth, and thin upper lip. Other unusual characteristics include heart defects (ventricular septal defects, atrial septal defects, and bicuspid aortic valve), hypoplasic phalanges, ambiguous genitalia, hypospadias, cryptorchidism, and inguinal hernia.

Because of the limited number of reported cases, clinical manifestations involving 5q35.3 microduplications only appear to be associated with short stature and microcephaly. Therefore, to delineate the phenotype-karyotype correlations more clearly, we summarized the clinical manifestations of patients involving or overlapping 5q35.3 duplications in Table 2. The age of the patients ranged from 2 years 8
Table 1

| Case | Sex | Pregnancy | Birth | Weight, kg | Length, cm | Weight, kg | Length, cm | Karyotype | Duplication of 5q35.3 | SNP array | Clinical findings |
|------|-----|-----------|-------|-----------|------------|-----------|------------|-----------|---------------------|-----------|-------------------|
| P1   | M   | G4P1      | 4.2   | 10        | 72         | 7         | 7          | 10        | 46, XY arr[hg19]5q35.3(178728830–202) N.A. Partial ADAMTS2 | Advanced maternal age; other organ and tissue anomalies | No apparent anomalies |
| P2   | F   | G1P0      | 3.9   | 9.5       | 72         | 8.5       | 70         | 9.5       | 46, XX arr[hg19]5q35.3(178754468–178931310) Paternal inherited | Advanced maternal age; ulnar abnormalities | No apparent anomalies |
| P3   | M   | G2P1      | 2.9   | 49        | 9          | 71        | 10.5       | 9          | 46, XY arr[hg19]5q35.3(178750377–3) Paternal inherited | Advanced maternal age; cardiac anomalies | No apparent anomalies |
| P4   | M   | G1P0      | 2.9   | 49        | 9          | 71        | 10.5       | 9          | 46, XY arr[hg19]5q35.3(178750377–3) Paternal inherited | Advanced maternal age; neonatal jaundice | No apparent anomalies |
| P5   | M   | G2P1      | NA    | NA        | 10         | NA        | 13         | NA        | 46, XY arr[hg19]5q35.3(178728830–202) N.A. Partial ADAMTS2 | Advanced maternal age; other organ and tissue anomalies | No apparent anomalies |
| P6   | F   | G2P1      | 4     | 52        | 7          | 70        | 5.5        | 6X inv(9) | 46, XX, inv(9) arr[hg19]5q35.3(178740070–178931310) Paternal inherited | Advanced maternal age; other organ and tissue anomalies | No apparent anomalies |

SNP = single-nucleotide polymorphism.

The duplicated region ranged from 0.26 to 6.4 Mb. Among the duplications, 6 of 18 patients were de novo, 4 of 18 were maternally inherited, and 8 of 18 patients were not available. The high incidence rate of clinical characteristics was as follows: short stature (16/18), growth retardation (15/18), microcephaly (14/18), intellectual disability (14/18), language retardation (12/18), and motor delay (11/18), which is consistent with previous reports of 5q duplications. Facial dysmorphisms are also important common manifestations for these patients and included: flat philtrum (12/18), long face (11/18), prominent nasal tip (11/18), thin upper lip (11/18), periorbital fullness (9/18), down-sloping palpebral fissures (9/18), strabismus (6/18), low-set ears (5/18), epicantthic folds (5/18), downturned mouth (4/18), a prominent nasal bridge (3/18), and hypertelorism (2/18). The irregular bone age was as follows: delayed (3/18), normal (2/18), and advanced (1/18). Mood swings and autistic symptoms were also reported in these patients (6/18).

Seven cases with similar overlapping 5q35.3 duplications are described in DECIPHER (patients 289927, 331005, 351756, and 300119) and ISCA databases (patients nssv 58214, nssv1608492, and nssv1608492) (Fig. 1). Patients 289927, 331005, and 351756 had a 16p13.2 microduplication, 5q35.3 microdeletion, and 7q36.1 microduplication, respectively, as well as the 5q35.3 duplication. In contrast, patient 300119 had a pure 5q35.3 duplication, presenting with truncal obesity, an abnormal facial shape, autistic behavior, and global developmental delay. Patient nssv 58214 presented with abnormalities of the skeletal system, a cleft upper lip, and Duane anomaly whose pathogenicity is uncertain. However, the pathogenicity of the duplicated region in the other 2 cases (nssv1608492 and nssv1608493) is largely benign, with the manifestation of developmental delay and/or other notable developmental or morphological phenotypes. Therefore, the pathogenicity of these duplicated regions is still uncertain.

Considering the follow-up outcomes of our patients, all children presented with normal growth and mental development, and there were no limb or facial feature anomalies. This differs from previous findings. P3 presented with a ventricular septal defect at birth, which was the only transitory symptom after birth. To further demonstrate the diverse clinical phenotypes, we made detailed comparisons of the cases encompassing the 5q35.2q35.3 duplication (Fig. 1).

According to the DECIPHER database, a total of 13 morbid genes exist in the 5q35.3 region (Table 3), which are associated with a diverse range of clinical phenotypes. The gene dosage effect appears to be involved in some abnormal clinical phenotypes. Our cases all share similar partial duplications of ADAMTS2 (OMIM 604539; chr5:178728830–178772431) (Fig. 1). ADAMTS2 contains 22 exons and is a member of the ADAMTS gene family. It encodes an enzyme that excises the N-propeptide of type I and type II procollagens. ADAMTS2 haploinsufficiency is associated with the dermatosparaxis type of Ehlers–Danlos syndrome (EDS; OMIM 225410) which is inherited in an autosomal recessive manner. EDS is a heterogeneous group of disorders that affect the fragility of soft connective tissues, leading to hypermobile joints and hyperextension of the skin and other organs and tissues. The dermatosparaxis type of this syndrome is characterized by extreme skin fragility, characteristic craniofacial features, easy bruising, and growth retardation.
| References     | Duplicated region | Age/sex | Inheritance | Growth retardation | Short stature | Microcephaly | Micrognathia | Long face | Epiarchic folds | Periorbital fullness | Palpebral fissures | Strabismus | Hypertelorism | Nose | Flat philtrum | Prominent/high nasal bridge | Prominent/bulbous nasal tip | Downturned mouth | Thin upper lip | Low set ears | Brachyotlipy | Heart defects | Miter delay | Language retardation | Intellectual disability | Bone age | Birth size | Others |
|---------------|------------------|---------|-------------|-------------------|---------------|--------------|--------------|-----------|----------------|--------------------|---------------------|-------------|---------------|------|--------------|-------------------------|---------------------------|----------------|-------------|-------------|-------------|-------------|-------------|-------------------|-------------------|---------|------------|---------|
| Chen et al.14  | 5q35.2q35.3      | 11 y   | De novo     | +                 | +              | +            | +            | +         | +              | NA                 | NA                  | +           | +             | +    | NA           | NA                      | NA                        | +             | NA          | +           | +            | +           | +            | NA                 | +                 | NA      | +          | +       |
| Kirchhoff et al.17 | 5q35.2q35.3      | 6.4 y  | De novo     | +                 | +              | +            | +            | +         | +              | NA                 | NA                  | +           | +             | +    | NA           | NA                      | NA                        | +             | NA          | +           | +            | +           | +            | NA                 | +                 | NA      | +          | +       |
| Franco et al.18 | 5q35.2q35.3      | >1.2    | De novo     | +                 | +              | +            | +            | +         | +              | NA                 | NA                  | +           | +             | +    | NA           | NA                      | NA                        | +             | NA          | +           | +            | +           | +            | NA                 | +                 | NA      | +          | +       |
| Kasnauksene et al.16 | 5q35.3          | 14.1 y | De novo     | +                 | +              | +            | +            | +         | +              | NA                 | NA                  | +           | +             | +    | NA           | NA                      | NA                        | +             | NA          | +           | +            | +           | +            | NA                 | +                 | NA      | +          | +       |
| Patient 1      | 5q35.2q35.3      | 11.1   | NA          | +                 | +              | +            | +            | +         | +              | NA                 | NA                  | +           | +             | +    | NA           | NA                      | NA                        | +             | NA          | +           | +            | +           | +            | NA                 | +                 | NA      | +          | +       |
| Patient 2      | 5q35.3           | 33.4 y | NA          | +                 | +              | +            | +            | +         | +              | NA                 | NA                  | +           | +             | +    | NA           | NA                      | NA                        | +             | NA          | +           | +            | +           | +            | NA                 | +                 | NA      | +          | +       |
| Patient 3      | 5q35.2q35.3      | 4.3 y  | NA          | +                 | +              | +            | +            | +         | +              | NA                 | NA                  | +           | +             | +    | NA           | NA                      | NA                        | +             | NA          | +           | +            | +           | +            | NA                 | +                 | NA      | +          | +       |
| Patient 4      | 5q35.2q35.3      | 14 y   | De novo     | +                 | +              | +            | +            | +         | +              | NA                 | NA                  | +           | +             | +    | NA           | NA                      | NA                        | +             | NA          | +           | +            | +           | +            | NA                 | +                 | NA      | +          | +       |
| Patient 5      | 5q35.2q35.3      | 11.5 y | NA          | +                 | +              | +            | +            | +         | +              | NA                 | NA                  | +           | +             | +    | NA           | NA                      | NA                        | +             | NA          | +           | +            | +           | +            | NA                 | +                 | NA      | +          | +       |
| Patient 6      | 5q35.3           | 8 y    | De novo     | +                 | +              | +            | +            | +         | +              | NA                 | NA                  | +           | +             | +    | NA           | NA                      | NA                        | +             | NA          | +           | +            | +           | +            | NA                 | +                 | NA      | +          | +       |
| Patient 7      | 5q35.2q35.3      | 35.0 y | NA          | +                 | +              | +            | +            | +         | +              | NA                 | NA                  | +           | +             | +    | NA           | NA                      | NA                        | +             | NA          | +           | +            | +           | +            | NA                 | +                 | NA      | +          | +       |
| Patient 8      | 5q35.2q35.3      | 2 y    | NA          | +                 | +              | +            | +            | +         | +              | NA                 | NA                  | +           | +             | +    | NA           | NA                      | NA                        | +             | NA          | +           | +            | +           | +            | NA                 | +                 | NA      | +          | +       |
| Patient 9      | 5q35.2q35.3      | 2 y    | NA          | +                 | +              | +            | +            | +         | +              | NA                 | NA                  | +           | +             | +    | NA           | NA                      | NA                        | +             | NA          | +           | +            | +           | +            | NA                 | +                 | NA      | +          | +       |
| Patient 10     | 5q35.2q35.3      | 2 y    | NA          | +                 | +              | +            | +            | +         | +              | NA                 | NA                  | +           | +             | +    | NA           | NA                      | NA                        | +             | NA          | +           | +            | +           | +            | NA                 | +                 | NA      | +          | +       |
| Patient 11     | 5q35.2q35.3      | 2 y    | NA          | +                 | +              | +            | +            | +         | +              | NA                 | NA                  | +           | +             | +    | NA           | NA                      | NA                        | +             | NA          | +           | +            | +           | +            | NA                 | +                 | NA      | +          | +       |

+ = feature present, − = feature absent, a = presumed from the patient picture in the paper, F = female, IQ = intelligence quotient, M = male, NA = not available.
There is currently no available evidence for the triplosensitivity in association with ADAMTS2. Moreover, P2 and P3 separately inherited the 5q35.3 duplication from their father, presenting without abnormal clinical phenotypes. Therefore, we speculate that the partial duplication of 5q35.3 (chr5: 17872830–178997692), including part of ADAMTS2, might be a benign variant. A partial RUFY1 duplication was also seen in P4; this gene might be involved in endolysosomal transport, which plays an important role in the development of Alzheimer disease. It is therefore likely that this gene has no evident relevance with our subject.

Our research has some limitations. First, the age of individuals at follow-up was typically too young to assess prospective growth and development, especially regarding language and intellectual disability. Table 2 shows that the youngest age reported in previous studies was 2 years 8 months, whereas our youngest subject was 13 months old; therefore, regular follow-up for our cases should be carried out in the future. Second, only 2 of the

### Table 3

| Gene       | OMIM   | Description                                      | Disease                                                                 |
|------------|--------|--------------------------------------------------|-------------------------------------------------------------------------|
| NSD1       | 606681 | Nuclear receptor binding SET domain protein 1    | Sotos syndrome 1, leukemia, acute myeloid, AML                           |
| SLC34A1    | 182309 | Solute carrier family 34 member 1                | Nephrolithiasis/osteoporois, hypophosphatemic, 1, falcion remtubular    |
|            |        |                                                  | syndrome 2, hypercalcemia, infantile, 2                                 |
| F12        | 610619 | Coagulation factor XII                            | Factor XII deficiency, angioedema, hereditary, type III                  |
| DDX41      | 608170 | DEAD-box helicase 41                              | Myeloproliferative/lymphoproliferative neoplasms, familial (multiple types), susceptibility to Ehlers-Danlos syndrome, spondyloystoplastric type, 1 |
| B4GALT7    | 604327 | Beta-1,4-galactosyltransferase 7                  | Pituitary hormone deficiency, combined, 2                               |
| PROP1      | 601538 | PROP paired-like homeobox 1                      | Dyksaratoisis condiqita, autosomal recessive 2                           |
| NHP2       | 606470 | NHP2 ribonucleaseprotein                         | Phosphohydroxylysimaunira                                                |
| PHYKPL     | 614683 | 5-phosphohydroxy-L-lysine phospho-lyase           | Night blindness, congenital stationary (complete), 1B, autosomal recessive Ehlers-Danlos syndrome, dermatosparasite type |
| GRM6       | 604096 | Glutamate metabotropic receptor 6                |                                                                          |
| ADAMTS2    | 604539 | ADAM metallopeptidase with thrombospondin type 1 motif 2 |                                                                          |
| LTC4S      | 246530 | Leukotriene C4 synthase                          | Leukotriene C4 synthase deficiency                                      |
| SGSTM1     | 601530 | sequestosome 1                                   | Paget disease of bone 3, frontotemporal dementia and/or amyotrophic      |
|            |        |                                                  | lateral sclerosis 3, Neurodegeneration with ataxia, dystonia, and gage    |
|            |        |                                                  | pauly, childhood-onset, myopathy, distal, with rimmed vacuoles           |
| FLT4       | 136352 | Fms-related tyrosine kinase 4                    | Lymphedema, hereditary, IA, hemangioma, capillary infantile              |

OMIM = Online Mendelian Inheritance in Man.
present couples chose to investigate whether their chromosomal duplications are inherited, which is not sufficient evidence to explain pathogenicity of the duplicated region. Additionally, because few reports of similar 5q35.3 duplications have been made previously, further research is needed to confirm our findings.

5. Conclusion
We analyzed 6 prenatal cases with similar 5q35.3 micro-duplications ranging from 177 to 269 kb involving part of the ADAMTS2 locus by SNP array. The application of molecular cytogenetic techniques provides an effective approach to improve the diagnosis rate of chromosomal micro-rearrangements and locate functional genes. Our report revealed that the partial 5q35.3 duplication (chr5: 178728830–178997692) might be benign and have no association with human disorders. However, the children involved in this study should undergo an assessment of their growth and intelligence during childhood and adulthood. All cases in our report currently present with normal physical development and clinical manifestations, with no apparent phenotypic abnormalities. This suggests the existence of phenotypic diversities associated with 5q duplications.

Author contributions
Conceptualization: Hongguo Zhang, Shibo Li, Ruixue Wang. Data curation: Qi Xi. Formal analysis: Qi Xi, Yuting Jiang. Funding acquisition: Ruizhi Liu. Investigation: Fagui Yue, Yang Yu, Yuting Jiang, Ruixue Wang. Methodology: Qi Xi, Yuting Jiang, Shibo Li. Project administration: Hongguo Zhang, Ruixue Wang. Software: Yuting Jiang. Supervision: Yang Yu, Hongguo Zhang, Shibo Li, Ruizhi Liu. Validation: Yang Yu, Ruizhi Liu, Ruixue Wang. Writing – original draft: Fagui Yue. Writing – review & editing: Ruixue Wang.

References
[1] Witters I, Van Buggenhout G, Moerman P, et al. Prenatal diagnosis of de novo distal 5q duplication associated with bygroma colli, fetal oedema and complex cardiopathy. Prenat Diagn 1998;18:1304–7.
[2] Zahnleiter D, Trautmann U, Ekici AB, et al. Familial short stature due to a 5q22.1-q23.2 duplication refrains the 5q duplication spectrum. Eur J Med Genet 2011;54:e521–4.
[3] Dikow N, Maas B, Gaspar H, et al. The phenotypic spectrum of duplication 5q35.2-q35.3 encompassing NSD1: is it really a reversed Sotos syndrome? Am J Med Genet A 2011;155A:2501–6.
[4] Rodewald A, Zankl M, Gley EO, et al. Partial trisomy 5q: three different phenotypes depending on different duplication segments. Hum Genet 1980;55:191–8.
[5] Levy B, Dunn TM, Kern JH, et al. Delineation of the dup5q phenotype by molecular cytogenetic analysis in a patient with dup5q/del 5p (cri du chat). Am J Med Genet A 2002;108:192–7.
[6] Douyard J, Hawley P, Shaham M, et al. Duplication of 5q15-q23.2: case report and literature review. Birth Defects Res A Clin Mol Teratol 2006;76:272–6.
[7] Manning M, Hodgins L. Professional Practice and Guidelines Committee:Array-based technology and recommendations for utilization in medical genetics practice for detection of chromosomal abnormalities. Genet Med 2010;12:742–5.
[8] Levy B, Wapner R. Prenatal diagnosis by chromosomal microarray analysis. Fertil Steril 2018;109:201–12.
[9] Miller DT, Adam MP, Aradhya S, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet 2010;86:749–64.
[10] Shahfer LG, Slovák ML, Campbell LJ. ISCN 2013: an international system for human cytogenetic nomenclature. Basel, Switzerland: S. Karger; 2013;138 p.
[11] Goldenberg P. An update on common chromosome microdeletion and microduplication syndromes. Pediatr Ann 2018;47:e198–203.
[12] Curry CJ, Loughman WD, Francke U, et al. Partial trisomy for the distal long arm of chromosome 5 (region q54 leads to qter). A newly clinically recognizable syndrome. Clin Genet 1979;15:454–61.
[13] Jones LA, Jordan DK, Tays K, et al. Partial duplication of the long arm of chromosome 5: a case due to balanced paternal translocation and review of the literature. Hum Genet 1979;31:37–42.
[14] Chen CP, Lin SP, Lin CC, et al. Molecular cytogenetic analysis of de novo dup(5)(q35.2q53.3) and review of the literature of pure partial trisomy 5q. Am J Med Genet A 2006;140:1594–600.
[15] Jamsheer A, Sowitska A, Simon D, et al. Bilateral radial agenesis with absent thumbs, complex heart defect, short stature, and facial dysmorphology in a patient with pure distal microduplication of 5q35.2-5q35.3. BMC Med Genet 2013;14:13.
[16] Knauskiene J, Cimbalistiene L, Ciuladate Z, et al. De novo 5q35.5 duplication with clinical presentation of Sotos syndrome. Am J Med Genet A 2011;155A:2301–7.
[17] Kirchhoff M, Bugzaard M, Bryndorf T, et al. MLPA analysis for a panel of syndromes with mental retardation reveals imbalances in 5.8% of patients with mental retardation and dysmorphic features, including duplications of the Sotos syndrome and Williams-Beuren syndrome regions. Eur J Med Genet 2007;50:33–42.
[18] Franco LM, de Ravel T, Graham BH, et al. A syndrome of short stature, microcephaly and speech delay is associated with duplications reciprocal to the common Sotos syndrome deletion. Eur J Hum Genet 2010;18:258–61.
[19] Zhang H, Lu X, Beasley J, et al. Reversed clinical phenotype due to a microduplication of Sotos syndrome region detected by arrayCGH: microcephaly, developmental delay and delayed bone age. Am J Med Genet A 2011;155A:1374–8.
[20] Zilina D, Reimand T, Tammur P, et al. Patient with dup(5)(q35.2-q35.3) reciprocal to the common Sotos syndrome deletion and review of the literature. Eur J Hum Genet 2013;21:202–6.
[21] Reis FG, Pinto IP, Minasi LB, et al. A rare case of a boy with de novo microduplication at 5q35.2q35.3 from central Brazil. Genet Mol Res 2017;16.
[22] Rice AM, McLysaght A. Dosage-sensitive genes in evolution and disease. BMC Biol 2017;15:78.
[23] Colige A, Nuytinck L, Hauser I, et al. Novel types of mutation responsible for the dermatosparactic type of Ehlers-Danlos syndrome (TypeVIIIC) and common polymorphisms in the ADAMTS2 gene. J Invest Dermatol 2004;123:636–63.
[24] Nicholson AC, Malik SB, Logsdon JM, et al. Functional evolution of ADAMTS genes: evidence from analyses of phylogeny and gene organisation. BMC Evol Biol 2005;5:11.
[25] Kelwick R, Desanlis I, Wheeler GN, et al. The ADAMTS (A Disintegrin and Metalloproteinase withThrombospondin motifs) family. Genome Biol 2015;16:1113.
[26] Malan P, Francomano C, Byers P, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet 2017;175:8–26.
[27] Brady AF, Demirdas S, Fourtel-Giguleux S, et al. The Ehlers-Danlos syndromes, rare types. Am J Med Genet C Semin Med Genet 2017;175:105–115.
[28] Kunkle BW, Vardarajan BN, Naj AC, et al. Early-onset Alzheimer disease and candidate risk genes involved in endolysosomal transport. JAMA Neurol 2017;74:1113–22.